Fortunately, in the last several years, two other agents (these are referred to as second-generation tyrosine kinase inhibitors) – dasatinib (Sprycel®) and nilotinib (Tasigna©) have both been shown to be at least equally effective (and likely better) in treating
CML. They have different side effects, but either can be used as initial therapy
for CML or after imatinib therapy.
This may be helpful to you:
http://www.medhelp.